lazabemide has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R | 1 |
| Fukuda, T; Nomoto, M | 1 |
2 other study(ies) available for lazabemide and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Humans; Isoenzymes; Liver; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Picolinic Acids; Rats; Selegiline | 1990 |
A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Dialysis; Drug Interactions; Female; Levodopa; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids | 1993 |